

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07H 21/04, C07K 14/705, 14/71, 14/715, 16/28, 16/46, C12Q 1/68, 1/00, 1/02, G01N 33/53, C12P 21/00, C12N 15/00, 15/01, 15/09, 15/10, 15/12, 1/00, A61K 38/17, 38/18, 39/395, 48/00</p>	A1	<p>(11) International Publication Number: WO 97/19952</p> <p>(43) International Publication Date: 5 June 1997 (05.06.97)</p>																							
<p>(21) International Application Number: PCT/US96/19128</p> <p>(22) International Filing Date: 27 November 1996 (27.11.96)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>08/562,663</td> <td>27 November 1995 (27.11.95)</td> <td>US</td> </tr> <tr> <td>08/566,622</td> <td>4 December 1995 (04.12.95)</td> <td>US</td> </tr> <tr> <td>08/569,485</td> <td>8 December 1995 (08.12.95)</td> <td>US</td> </tr> <tr> <td>08/570,142</td> <td>11 December 1995 (11.12.95)</td> <td>US</td> </tr> <tr> <td>08/583,153</td> <td>28 December 1995 (28.12.95)</td> <td>US</td> </tr> <tr> <td>08/599,455</td> <td>22 January 1996 (22.01.96)</td> <td>US</td> </tr> <tr> <td>08/638,524</td> <td>26 April 1996 (26.04.96)</td> <td>US</td> </tr> <tr> <td>08/708,123</td> <td>3 September 1996 (03.09.96)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): MILLENIUM PHARMACEUTICALS, INC. [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): TARTAGLIA, Louis, A. [US/US]; Apartment 6, 104 Coolidge Hill Road, Watertown, MA 02172 (US). TEPPER, Robert, I. [US/US]; 53 Laurel Road, Weston, MA 02193 (US). CULPEPPER, Janice, A.</p>	08/562,663	27 November 1995 (27.11.95)	US	08/566,622	4 December 1995 (04.12.95)	US	08/569,485	8 December 1995 (08.12.95)	US	08/570,142	11 December 1995 (11.12.95)	US	08/583,153	28 December 1995 (28.12.95)	US	08/599,455	22 January 1996 (22.01.96)	US	08/638,524	26 April 1996 (26.04.96)	US	08/708,123	3 September 1996 (03.09.96)	US	<p>[US/US]; 1734 Beacon Street, Brookline, MA 02146 (US). WHITE, David, W. [US/US]; 393 Pine Street, Holbrook, MA 02343 (US).</p> <p>(74) Agent: FASSE, J., Peter; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
08/562,663	27 November 1995 (27.11.95)	US																							
08/566,622	4 December 1995 (04.12.95)	US																							
08/569,485	8 December 1995 (08.12.95)	US																							
08/570,142	11 December 1995 (11.12.95)	US																							
08/583,153	28 December 1995 (28.12.95)	US																							
08/599,455	22 January 1996 (22.01.96)	US																							
08/638,524	26 April 1996 (26.04.96)	US																							
08/708,123	3 September 1996 (03.09.96)	US																							
<p>(54) Title: THE OB RECEPTOR AND METHODS OF DIAGNOSING AND TREATING WEIGHT</p> <p>(57) Abstract</p> <p>The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses <u>obR</u> nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an <u>obR</u> transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate <u>obR</u> gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.</p>																									

BEST AVAILABLE COPY